cnbc_topnews

Greg Abel earns solid scorecard from Berkshire shareholders after first annual meeting

greg abel ran his first berkshire hathaway annual meeting as the guy in charge, and shareholders mostly liked what they saw. the reviews were positive — "very solid. no misspoke words. thorough answers," said steve check of check capital management. david kass, a finance professor and decades-long shareholder, said he grew more confident after seeing abel's performance.

abel spent nearly an hour walking through berkshire's major businesses — railroad, energy, insurance, retail — with a level of operational detail that felt more like an investor day than past meetings. he talked about ai tools at bnsf railway and data center demand boosting the utility business. shareholders noted the shift: abel focuses on operations, while buffett focused on investing.

one disappointment: buybacks. berkshire repurchased $235 million of stock in q1, barely more than the $226 million it bought on march 4 alone. "i'm disappointed in the lack of significant buybacks," check said. "they bought much more at this valuation before."

source: cnbc_topnews
sentiment: +0.30 · impact: 0.40

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds